-+ 0.00%
-+ 0.00%
-+ 0.00%

Rohto Pharmaceutical Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall St·11/15/2026 23:19:08
Listen to the news

Last week, you might have seen that Rohto Pharmaceutical Co.,Ltd. (TSE:4527) released its half-yearly result to the market. The early response was not positive, with shares down 9.3% to JP¥2,446 in the past week. Statutory earnings per share fell badly short of expectations, coming in at JP¥25.94, some 21% below analyst forecasts, although revenues were okay, approximately in line with analyst estimates at JP¥179b. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

earnings-and-revenue-growth
TSE:4527 Earnings and Revenue Growth November 15th 2026

Following the latest results, Rohto PharmaceuticalLtd's ten analysts are now forecasting revenues of JP¥374.4b in 2027. This would be a satisfactory 4.4% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 9.2% to JP¥160. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥373.5b and earnings per share (EPS) of JP¥162 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

Check out our latest analysis for Rohto PharmaceuticalLtd

It will come as no surprise then, to learn that the consensus price target is largely unchanged at JP¥3,390. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Rohto PharmaceuticalLtd, with the most bullish analyst valuing it at JP¥3,840 and the most bearish at JP¥2,800 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's pretty clear that there is an expectation that Rohto PharmaceuticalLtd's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 9.1% growth on an annualised basis. This is compared to a historical growth rate of 13% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 3.9% per year. Even after the forecast slowdown in growth, it seems obvious that Rohto PharmaceuticalLtd is also expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Rohto PharmaceuticalLtd analysts - going out to 2029, and you can see them free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Rohto PharmaceuticalLtd .